EUCTR2015-002272-24-SE进行中（未招募）1 期
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, at least 18 years of age at time of Screening.
- •2. Screening laboratory result indicating HCV GT3 infection.
- •3. Chronic HCV infection.
- •4. Subject must be treatment-naïve.
- •5. Subjects must be non-cirrhotic.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 310
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1. History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs.
- •2. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.
- •3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.
- •4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).
- •5. HCV genotype performed during screening indicating co-infection with more than one HCV genotype.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)EUCTR2015-002272-24-GBAbbVie Deutschland GmbH & Co. KG506
进行中（未招募）
1 期
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)Chronic HCV Genotype 3 InfectionMedDRA version: 18.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-002272-24-DEAbbVie Deutschland GmbH & Co. KG460
已完成
3 期
A Clinical Trial to study the effect of Ulipristal Acetate Tablets 30 mg in Women requiring emergency contraceptioCTRI/2019/09/021343Synokem Pharmaceuticals Ltd102
已完成
3 期
A Clinical Trial to study the effect of Oxaceprol SR Tablets for the treatment of patients with OsteoarthritisCTRI/2019/04/018689Synokem Pharmaceuticals Ltd219
已完成
不适用
A Randomized, Open Label, Active-controlled, Multiple Dosing and Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of YH4808 after Postprandial Oral Administration in Healthy VolunteersKCT0000695Yuhan20